In East Africa, Streptococcus pneumoniae is a common and serious, but potentially preventable, human immunodeficiency virus type 1 (HIV-1)-associated pathogen. For 54 HIV-1-infected women, baseline levels of capsule-specific antibody to 2 of 4 pneumococcal serotypes were lower than levels in 15 seronegative women (P õ .05). After immunization, specific antibody to all 4 serotypes increased in HIV-1-infected and -uninfected women (P õ .05). Convalescent levels for 2 of 4 serotypes were greater in seronegative women, but the levels were not different between HIV-1-infected women with (n Å 21) or without (n Å 33) prior invasive pneumococcal disease. The baseline functional activity to kill S. pneumoniae type 14 was lower in HIV-1-infected than -uninfected women but also rose significantly in all groups after immunization. It is concluded that HIV-1 infection in Kenyan women is associated with decreased levels of natural antibody to selected pneumococcal capsular serotypes, but the vaccine is immunogenic in these patients who are at high risk of invasive pneumococcal disease.
The infections that complicate human immunodeficiency viKenya, including infected women who had recovered from invasive S. pneumoniae infection. rus type-1 (HIV-1) disease in Africa are quite different than those in the United States and Europe. Streptococcus pneumoniae infection rather than Pneumocystis infection is prominent, Methods as are Salmonella infections other than those due to S. typhi, tuberculosis, and herpes zoster [1, 2] . In Kenya, invasive pneuStudy population. We investigated women from a homogeneous, prospectively monitored population of poor commercial sex mococcal disease affects 4% of HIV-1-infected women per workers living in the same lower-class suburb in Nairobi [2, 5] .
year (compared with 1% in the US) and has a recurrence rate Three groups were examined: 15 HIV-1-seronegative women, of 26% [2, 3] . Thus, the number of cases of pneumococcal 33 HIV-1-infected women without known prior pneumococcal disease in HIV-1-infected persons in Africa is far greater than disease, and 21 HIV-1-infected women who had recovered from that in industrialized nations. When a disease is so prevalent invasive pneumococcal disease [2] . Pneumococcal disease was and resources are few, as in Africa, preventative measures, defined as radiographically confirmed pneumonia or sinusitis, priparticularly immunization, are likely to be cost-effective. Bemary bacteremia, or otitis media, each in association with a credicause the polysaccharide capsule of S. pneumoniae is its prible clinical syndrome and positive culture for S. pneumoniae. None mary virulence factor and because antibodies to the capsule of the women who were considered to be free from pneumococcal are the primary mechanism of defense against this organism disease had had symptoms or signs of or therapy for pneumococcal disease within the preceding 2.8 years of observation. Of the [4] , we measured levels of capsule-specific IgG in baseline women with invasive pneumococcal disease, 10 were bacteremic sera and in response to pneumococcal polysaccharide capsule ride serotypes and stored at 070ЊC until testing. sule-specific IgG were measured as previously described [6] , us- capsular type tested, type 14 (R 2 Å .51, P õ .02; figure 1A ).
Statistics. Differences in levels of capsule-specific IgG and
Preimmunization levels were significantly lower in both HIVkilling activity in serum were compared among clinical groups by 1-infected groups compared with levels in the seronegative analysis of variance (for 3 groups) and unpaired two-tailed t test group. Similar to results by ELISA, all groups showed a sig- disease (P õ .03).
Results Discussion
Pneumococcal disease commonly complicates HIV-1 infec-CD4 cell counts and baseline levels of pneumococcal capsule-specific IgG. At the time of immunization, the mean tion in persons in East Africa and worldwide [2, 12] . Recommendations for use of pneumococcal vaccine in this compro-({ SE) CD4 T cell count in HIV-1-seronegative women was 929 { 68 cells/mL; in the HIV-1-infected women without mised population [13, 14] are predicated on the assumptions that low levels of antibody specific for the common capsular known prior pneumococcal disease, it was 330 { 37 cells/mL, and in those with prior pneumococcal infection it was 189 { serotypes predispose to infection and that the vaccine elicits significant increases in these antibodies. We have demonstrated 37 cells/mL. Despite the lower number of CD4 T cells in the HIV-1-infected patients with previous pneumococcal disease, that HIV-1 infection in Kenyan women is associated with decreased levels of natural antibody to selected pneumococcal baseline levels of capsule-specific IgG were similar to those Table 1 . IgG-specific response to pneumococcal capsular polysaccharides in HIV-1-infected and -seronegative women, Nairobi, Kenya, 1989-1992.
HIV-1-infected persons after pneumococcal HIV-1-seronegative controls (n Å 15) HIV-1-infected controls (n Å 33) disease (n Å 21) NOTE. Before and after responses are in mg/mL; fold rise responses are median (% § 2). For each serotype in each group, capsule-specific IgG levels increased significantly 1 month after immunization compared with preimmunization levels (P õ .05; paired t test).
* P õ .05 compared with HIV-1-seronegative control subjects. capsular serotypes. The serotypes tested were those commonly prior S. pneumoniae disease, whose risk of recurrent disease is quite high (26% in this population) [2, 3] . Recurrences are most causing disease in Kenya [2] . Other factors likely also contribute to the increased risk of S. pneumoniae disease among these often due to different serotypes, and these patients generate a significant response to immunization that is similar to that of HIV-HIV-1-infected patients. In this regard, we have recently shown that levels of antibody to pneumolysin, the major pneu-1-infected women without known prior disease. Determining the duration of these responses will help to establish the vaccine's mococcal toxin associated with tissue invasion and the development of bacteremia, are also depressed during HIV-1 infection clinical benefit. Indeed, the critical issue remains whether the vaccine is effective (and cost-effective) in HIV-1-infected patients, a [15] . Moreover, defects in mucosal defense, phagocytic cell function, and complement activation, all of which are required population at increased risk of invasive pneumococcal disease, in East Africa and worldwide. for protection against the organism, may also be impaired [12] .
Regardless of other host defense mechanisms, antibodies to the bacteria's polysaccharide capsule are considered the principal
